Open access peer-reviewed chapter

EBV Genome Mutations and Malignant Proliferations

Written By

Sylvie Ranger-Rogez

Submitted: 01 May 2020 Reviewed: 16 June 2020 Published: 19 August 2020

DOI: 10.5772/intechopen.93194

From the Edited Volume

Epstein-Barr Virus - New Trends

Edited by Emmanuel Drouet

Chapter metrics overview

701 Chapter Downloads

View Full Metrics


The Epstein-Barr virus (EBV) is a DNA virus with a relatively stable genome. Indeed, genomic variability is reported to be around 0.002%. However, some regions are more variable such as those carrying latency genes and specially EBNA1, -2, -LP, and LMP1. Tegument genes, particularly BNRF1, BPLF1, and BKRF3, are also quite mutated. For a long time, it has been considered for this ubiquitous virus, which infects a very large part of the population, that particular strains could be the cause of certain diseases. However, the mutations found, in some cases, are more geographically restricted rather than associated with proliferation. In other cases, they appear to be involved in oncogenesis. The objective of this chapter is to provide an update on changes in viral genome sequences in malignancies associated with EBV. We focused on describing the structure and function of the proteins corresponding to the genes mentioned above in order to understand how certain mutations of these proteins could increase the tumorigenic character of this virus. Mutations described in the literature for these proteins were identified by reporting viral and/or cellular functional changes as they were described.


  • Epstein-Barr virus
  • lymphoma
  • carcinoma
  • mutation
  • sequence
  • next generation sequencing

1. Introduction

Epstein-Barr virus (EBV), a ubiquitous gamma-herpesvirus, infects the vast majority of the worldwide human population. This virus was initially discovered in cultured lymphoma cells from patients with Burkitt’s lymphoma (BL) in 1964 [1]. During the primary infection, EBV infects epithelial cells of the oropharynx where it actively replicates and also infects B cells where it establishes a life-long latency in the form of an episome located in the host cell nucleus. During latency, EBV may produce nine viral latency proteins, including six so-called “Epstein-Barr Nuclear Antigens” (EBNA1, -2, -3A, -3B, -3C, and -LP), involved in transcriptional regulation, and three “Latent Membrane Proteins” (LMP1, -2A, and -2B), mimicking signals needed for B cell maturation, as well as two small noncoding RNAs (EBER-1 and EBER-2), BamHI-A rightward transcripts (BARTs), and miRNAs. Four different latency programs can be identified, based on the proteins that are expressed (Table 1). EBV primary infection, which occurs more often in childhood, is usually asymptomatic in children, whereas it may be responsible for infectious mononucleosis (IM) in teenagers or young adults in western countries. In addition to this nonmalignant disease, EBV can also be associated with diverse malignant pathologies. In particular, EBV is involved in the development of several malignancies of lymphoid origin including endemic Burkitt’s lymphoma [2], nasal NK/T lymphoma [3], some Hodgkin’s lymphoma [4], and B- or T-cell lymphoproliferations in immunocompromised patients [5]. It is also implicated in epithelial malignancies such as undifferentiated nasopharyngeal carcinoma (NPC) [6] and 10% of cases of gastric carcinoma [7]. Although populations from all geographic areas are infected by the virus, the incidence of the pathologies in which it occurs varies significantly depending on the region [8]. For example, BL occurs mainly in children living in sub-Saharan Africa [9], and the prevalence of NPC is particularly high in adults living in Southern China, Southeast Asia, and Northern Africa [10]. The differences observed in the geographic distribution of these pathologies suggest that there could be various genetic variants of EBV, of different global distributions, and with different levels of transforming capacity. This question of a specific disease variant is raised by many authors and is still being debated. In this chapter, we wish to take inventory of the state of knowledge concerning the variability observed on the most mutated genes among all EBV genes and the possible implications in human pathology.

ProgramEBV expressed proteinsActive promotersB cell type
Latency IIIGrowthEBNA-1, -2, -3A, -3B, -3C, -LPInitially WpNaive B cells
LMP-1, -2A-, -2BThen Cp
LMP promoters
EBER-1 and -2p
Latency IIDefaultEBNA-1Qp, EBER-1 and -2p
LMP-1, -2A, -2BLMP promoters
Latency ILatencyEBNA-1Qp, EBER-1 and -2pResting B cells
Latency 0No protein or LMP-2ALMP-2ApMemory B cells

Table 1.

Proteins expressed during the different latency programs.


2. Evolving knowledge of the EBV genome

The fact that the viral genome is relatively large (175 kb), that it is made up of DNA, therefore less variable than if it was an RNA genome, and that it carries repetitive regions, limited its sequencing for a long time. The first published sequences were small fragments of the B95-8 genome; then, the entire B95-8 genome was sequenced in 1984 [11]. The B95-8 strain was the first cultured EBV cell line able to secrete large amounts of viral particles into the culture medium. It was originally obtained from a spontaneous human lymphoblastoid cell line (LCL) established from a North American case of infectious mononucleosis, the 883L cell line, whose virus was used to transform lymphocytes from a cotton top marmoset. Since it was the first strain with a fully published genome, B95-8 has been extensively studied and mapped for transcripts, promoters, and open reading frames.

This first EBV whole genome sequencing was followed by others, and complete viral genome sequences of the cell lines AG876, originating from a Ghanaian case of African BL [12] and GD1, obtained from cord B cells infected with EBV from saliva of an NPC patient in Guangzhou, China [13] were published. Sequences of some genes, mainly latency genes, were also studied, especially in lines established from patients [14, 15]. B95-8, GD1, and AG876 were sequenced by conventional shotgun sequencing (Sanger’s method). The comparison of sequences obtained for various cell lines revealed the existence of two types of EBV: type 1 or A, of which B95-8 can be considered as the prototype, and type 2 or B, exemplified by AG876. The main difference between the two types concerns the EBNA2 gene, with only 70% identity at the nucleotide level and 54% identity in the protein sequence [16]. Additional variations have also been observed in the EBNA3 genes, but to a lesser extent: 10, 12, and 19% of base pair differences for EBNA3A, 3B, and 3C, respectively [17]. The comparison of viral sequences also highlighted that the B95-8 cell line has a significant 11.8 kb deletion (positions 139,724–151,554) corresponding to some of the BART miRNA genes, one of the origins of lytic replication [11], the LF2 and LF3 genes, and a part of the LF1 gene. More complete sequence comprising the B95-8 sequence supplemented with a Raji fragment at the level of deletion has been constructed. It was annotated in 2010 as RefSeq HHV4 (EBV) sequence NC_007605 and is now used as a wild-type strain reference [18].

As adaptation of the virus to in vitro culture is possible, thus generating a bias in the results, some authors have preferred to sequence the viral genome directly in samples from patients. Therefore, the sequences GD2, from a Guangzhou NPC biopsy, and HKNPC1, from a Hong Kong NPC biopsy, were published [19, 20], both using a more recent sequencing technique, “next generation sequencing” (NGS). This technology can be used directly on samples or after enrichment, which avoids artifacts due to cellular DNA. Enrichment can be achieved by PCR or cloning into F-factor plasmids, but most frequently, it is carried out using target DNA capture by hybridization. NGS delivers a wealth of information and requires extensive bioinformatic analysis. This technology has made it possible to rapidly increase the number of fully sequenced viral genomes originating from healthy subjects or patients and thus obtain more information.


3. The most variable regions of the genome

Authors who sequenced the entire viral genome and analyzed the genomic variations came to the conclusion that the latent genes harbored the highest numbers of nonsynonymous mutations [20, 21, 22, 23, 24]. For example, Liu et al. [25] compared the sequences of nine strains of EBV to GD1, of which they were most closely related, and showed that latency genes were the most mutated. In this study, latent and tegument genes were found to harbor 58.4 to 84.3% of all nonsynonymous mutations detected for each genome. Santpere et al. [26] found that latent genes were twice as mutated as lytic genes. The observation that the latent genes harbor more nucleotide diversity than lytic genes was made regardless of the type of pathology: nasopharyngeal carcinoma [20, 21], NK/T lymphoma [27], endemic Burkitt’s lymphoma [22], Hodgkin’s lymphoma [22], posttransplant lymphoproliferative disease [22], gastric carcinoma [25], lung carcinoma [23], and also strains originating from infectious mononucleosis [22] or healthy subjects [26]. Why latent genes are the most variable is not clear today. By analyzing their data according to the Yang model [28], Santpere et al. [26] showed that the lytic genes had an evolutionary constraint close to that of the host: a strong purifying selection was objectified for 11 lytic genes. However, signatures of accelerated protein evolution rates were found in coding regions related to virus attachment and entry into host cells. The latency genes, on the other hand, show a positive selection, perhaps in relation to the MHC, which can be the cause of their large diversity. Changes in amino acids (aa) often occur in immune epitopes. Amino acid changes in CD8+ epitopes were described in all latent proteins, while changes in CD4+ epitopes were shown only for EBNA1 and -2 and LMP1 and -2 [20]. However, most codons of the EBNA3 gene under positive selection are not cytotoxic T-lymphocyte epitopes: either there are epitopes not described to date or the selection relates to other functionalities. The selection of mutants may depend on a difference in immunity in relation to the geography and/or capacity of a strain to infect and persist.


4. Variability of main latency proteins

After the virus enters a host cell, the genome circularizes through recombination of the terminal repeats (TRs) located at each end of the genome to form an episome that will be chromatinized and methylated in the same way as the human genome. Latent transcription programs in B cells are due to the differential activity of epigenetically regulated promoters and take place in three successive waves. The EBNA2 and EBNA-LP, as well as BHRF1, a bcl2 homolog, are the first viral proteins to be expressed, under the dependence of Wp promoter. The two expressed EBNAs and the cellular factor recombination signal-binding protein for immunoglobulin Kappa J region (RBP-Jk) activate then the Cp promoter, which drives the expression of all of the EBNA proteins, while Wp becomes progressively hypermethylated; the transcription will gradually be under Cp control. Subsequently, LMP1, LMP2A, and LMP2B proteins are expressed due to activation of their respective promoters. During latency I or II, Qp promoter controls EBNA1 expression, and Cp methylation is responsible for the five other EBNA silencing. Methylation does not control the Qp promoter, which is switched off by binding to a repressor protein.

As previously developed, latency proteins show the most sequence variations, and among them, EBNA1, EBNA2, EBNA-LP, and LMP1 are the most mutated. The main properties of these proteins are reported in Table 2.

4.1 EBNA1

EBNA1, expressed in both latent and lytic EBV infections, was the first EBV protein detected. EBNA1, whose structure (Figure 1) and functions have largely been studied [29, 30], is a 641 aa protein. However, EBNA1 proteins frequently exhibit size variations due to differing numbers of gly-ala repeats (aa 89–325). During latency, EBNA1 is the only protein expressed in all forms of latency in proliferating cells and also in all EBV associated malignancies. EBNA1, which acts as a homodimer, is essential for initiating EBV episome replication before mitosis, once per cell cycle, and mitotic segregation of EBV episomes, thus for the maintenance of EBV episome in latently infected cells [31]. The EBNA1 DNA-binding domain is essential but not sufficient for the replication function, and the N-terminal half of EBNA1 is also required. Two EBNA1 regions (aa 8–67 and aa 325–376) are particularly important for this activity, and the point mutations G81 or G425 enhance EBNA1-dependent DNA replication. Inversely, the EBNA1 aa 395–450 region mediates an interaction with the human ubiquitin-specific protease, USP7, which may negatively regulate replication. The partitioning of EBV episomes in two dividing cells requires two viral components: the ori P FR element and EBNA1, mainly the central Gly-Arg region aa 325–376 and secondarily the aa 8–67 sequence. EBNA1 also activates the expression of other latency genes participating in immortalization: the regions involved are the central Gly-Arg sequence and the 61–89 region. Interaction with the recognition sites located on FR, DS of ori P, and Bam-HI-Q takes place through binding sites located in the C-terminal of EBNA1 (aa 459-607), sequence which also mediates the dimerization of EBNA1 (aa 504–604). Through its interaction with both human casein kinase CK2 (aa 383–395) and cellular ubiquitin-specific protease USP7 (aa 442–448), EBNA1 is also able to disrupt promyelocytic leukemia protein (PML) bodies and degrade PML. In addition to its role in latent infection, EBNA1 can therefore participate in lytic infection by overcoming suppression by PML proteins [32]. Indeed, PML proteins and nuclear bodies were found to suppress lytic infection by EBV. Recently [33], organization in an oligomeric hexameric ring form was described for the EBNA1 DNA-binding domain, the oligomeric interface pivoting around residue T585. Mutations occurring on this residue had both positive and negative effects on EBNA1-dependent DNA replication and episome maintenance.

Figure 1.

Schematic representation of basic structure of EBNA1 protein with the different motifs and their position. Gly-Arg: region rich in Gly-Arg; Gly-Ala: Gly-Ala repeats; CK2: interaction with human casein kinase, CK2; USP7: interaction with the human ubiquitin specific protease, USP7; DNA binding: DNA-binding domain; Dimerization: region that mediates the dimerization of EBNA1. The different mutations discussed are noted.

Based on polymorphisms observed at 15 codons, Bhatia et al. [14] reported two strains named P (prototype) and V (variant), each having two subtypes defined by the aa at position 487 (P-ala, P-thr, V-pro, and V-leu). They detected mostly the P-thr and the V-leu variants, respectively, in African and American BL tumors, but these findings were not confirmed by another group who reported different spectra of EBNA1 subtypes according to different geographical areas in both healthy patients and BL tumors [34]. A fifth subtype, V-val, was later recognized in South-East Asia and was found to be prevalent in NPC samples by numerous authors [20, 35, 36, 37]. These findings suggest that the V-val variant might adapt particularly well to the nasopharyngeal epithelium or that this strain possesses an increased oncogenic potential. Indeed, most of the variant codons, localized in the DNA-binding domain, may have an impact on the EBV phenotype resulting in impaired ability to transform B-lymphocytes [30]. However, other reports observed that this subtype had no tumor-specific expression [38], and it is likely that it probably represents a dominant EBNA1 subtype in Asian regions, not found in other areas of the world [8, 23, 25]. The P-thr subtype is the most commonly observed in peripheral blood of American and African subjects as well as in African tumors. In our experience, P-thr is also the most prevalent in France and particularly in the course of lymphoproliferative diseases.

Apart from these mutations, others have been reported. For example, Borozan et al. [39] looked at gastric carcinomas and mainly found two mutations already described in NPC, H418L and A439T, located outside the DNA-binding domain and common in both NPC and GC but uncommon in other EBV isolates, from lymphomas or healthy subjects. They also described a new mutation, T85A, positioned in the region required for transcriptional activation of other latency genes and thus able to modify this function. Wang et al. [23] described the substitution T585I. T585 is subject to substitutions, and T585 polymorphism is found frequently in NPC tumors and Burkitt’s lymphoma. T585I was previously found, and this strain was defective in replication and maintenance of the viral episome [40], as well as deficient in suppressing lytic cycle gene transcription and lytic DNA replication.

In summary, EBNA1 V-val variant seems to be a geographic variant almost exclusively present in South-East Asia. Conversely, mutations T85 and T585, which occur in functional regions of the protein, could have biological consequences and especially the substitution T585I, which promotes lytic replication and is found in NPC.

4.2 EBNA2

EBNA2, a 487 aa protein, is expressed in vivo during latency III shortly after infection of B cells or in lymphomas occurring in immunocompromised patients and in LCL. As mentioned above, the variations in EBNA2 make it possible to classify EBV as types 1 and 2 (or A and B) since only 70% identity at the nucleotide level and 54% homology in the protein sequence were observed. The overall structure of the EBNA2 protein (Figure 2) is characterized by poly-P and poly-RG areas, this last one being a protein-protein and protein-nucleic acid interaction domain important for efficient cell growth transformation, and nine regions conserved throughout the gene [41]. EBNA2 acts principally as a transcription factor and contains three categories of domains critical for its transcription regulation function: transactivation domains (TAD), self-association domains (SAD), and nuclear localization signals (NLS). EBNA2 does not bind directly to DNA. It uses cell proteins as adapters to access viral or cellular enhancer and promoter sites. The C-terminal TAD (aa 448–471) is able to recruit components of basic transcriptional machinery as well as chromatin modifiers and can bind to the viral coactivator EBNA-LP, while the N-terminal TAD (aa 1–58) cannot bind EBNA-LP, although its activity can be enhanced by this protein. Two SADs (aa 1–58 and 97–121), separated by the poly-proline stretch, were identified in the N-terminal region [42]. An additional third one has been reported, localized in a nonconserved region, and flanked by the second SAD and the adapter region [43]. EBNA2 contributes to B-cell immortalization, and it has been demonstrated that type 1 EBV, which is predominantly found in EBV-associated diseases, immortalizes B cells in vitro much more efficiently than type 2 [44], which is predominantly determined by sequence variation in the C-terminus of EBNA2 [45]. During the early events of EBV infection in resting B cells, EBNA2 initiates the transcription of a cascade of primary and secondary viral and cellular target genes and therefore is responsible for the initiation of immortalization by reprogramming the resting state into a proliferative state. For this, EBNA2 interacts with chromatin remodelers and as a transcription factor cofactor [46]. Mühe et al. [47] demonstrated that the first 150 N-terminal aa of EBNA2 are important for the initiation of immortalization. EBNA2 is also involved in immortalization maintenance; the region implicated here (aa 295–378) includes the conserved regions CR5 (aa 295–307) and CR6 (aa 320–326), particularly important for this function. CR5 mediates the contact between EBNA2 and SKIP (Ski-interacting protein), and CR6 is the CBF1 (C promoter-binding factor 1) or RBP-Jk targeting domain. Mechanisms to initiate and maintain B cell immortalization are not completely understood today.

Figure 2.

Schematic representation of basic structure of EBNA2 protein with the different motifs and their position. The two transactivation domains (TADs), the three self-association domains (SADs), and the two nuclear localization signals (NLSs) are mentioned. Poly P: area rich in P; PolyRG: area rich in RG; CR5: conserved region 5, which interacts with SKIP (Ski-interacting protein); CR6: conserved region 6, which interacts with CBF1 (C promoter-binding factor 1). The different mutations discussed are mentioned.

Wang et al. [41], working on 25 EBV-associated GCs, 56 NPCs, and 32 throat washings from healthy donors in Northern China, described 4 EBNA2 subtypes according to the presence of a deletion, namely subtypes E2-A (no aa deletion), E2-B (aa 294Q deletion), E2-C (aa 357K and 358G deletion), and E2-D (aa 357K, 358G, and 294Q deletion). The E2-A subtype exhibited six nonsilent mutations, P291T, R413G, I438L, E476G, P484H, and I486T; the substitution P291T was present in six NPC E2-D and six NPC E2-C. The substitution R413G was detected in E2-C for one patient. They found that E2-A and E2-C were dominant in the samples they analyzed and that the E2-D pattern was detected only in the NPC specimens. The mutation R163M was detected in all samples. This mutation has previously been described worldwide and in different diseases.

Mutations 357 and 358 occurred in the RG domain (aa 335–362), a downregulator of EBNA2 activation of the LMP1 promoter [48]. Moreover, aa 357–363 (KGKSRDK) constitutes the PKC phosphorylation site, which can reduce the amounts of EBNA2/CBF1 complex formed. EBNA2 is suspected to be involved in the development of malignancies as a result of sequence variations most frequently affecting its regulation function.

Interestingly, EBNA2 entire-gene deletion has been shown in some endemic BL cell lines such as P3HR1, Daudi, Sav, Oku, and Ava [49]; it remains to determine if this deletion occurs classically in vivo in African BL.

In short, geographic variants were not formally demonstrated for EBNA2. Among the described mutations, the most interesting are those occurring in the PKC phosphorylation site because they can activate the Cp and/or LMP1p and thus increase the production of latency proteins.

4.3 EBNA-LP (EBNA-leader protein)

EBNA-LP, like EBNA2 and concomitantly with EBNA2, is expressed shortly after the infection of B cells in healthy individuals as well as in EBV-related malignant diseases in immunodeficient patients and LCLs. EBNA-LP acts mostly as a coactivator of the transcriptional activator EBNA2, thus inducing the expression of some cellular genes, including cyclin D2 [50], or viral genes, that is, LMP1 [51], LMP2b, and Cp and therefore having an important role in B cell immortalization. EBNA-LP also can directly interact with several cell proteins such as tumor suppressors or proteins involved in apoptosis or cell cycle regulation.

EBNA-LP is comprised of a variable number of 66 aa repetitive units, corresponding to the variable number of W1 and W2 exons located in the EBV internal repeat IR1, followed by a unique 45 aa domain, encoded by two unique 3′ exons Y1 and Y2 (Figure 3). Therefore, EBNA-LP protein may vary in size according to the number of W1–W2 repeats contained in each EBV isolate. By convention, the protein annotation is based on a single W repeat isoform (Figure 4). In this configuration, the protein has 110 aa. Conserved regions were identified in the N extremity of the protein (CR1 to CR3, respectively, aa 11–33, 45–52, and 55–62, implicated in EBNA2 binding), and in the C-terminal region (CR4 and CR5, respectively, aa 76–82 and 101–110). CR3 and a serine within W2 (S35) were demonstrated to be important for EBNA2 coactivation. EBV-mediated B cell immortalization maps to the W1W2 repeated domains and requires at least two IR1 repetitions to be effective, but a number greater than or equal to 5 is optimal [53]. Some interactions with cell proteins are mediated by the repeated W1W2 N-terminus [54]. EBNA-LP gene transcription initiates from the W promoter (Wp) residing in each IR1 repeat during the early stages of infection, and multiple EBNA-LP protein isoforms are produced. During the later stages of infection and in LCLs, transcription initiates from the C promotor (Cp) [55]. The level of transcription initiated by Cp compared to Wp varies according to different circumstances [56].

Figure 3.

Schematic representation of the IR1 region of EBV genome (according to Ref. [52]). The promoters Wp, Cp, and Qp are represented, as well as the different proteins expressed according to the stage of infection.

Figure 4.

Sequence of EBNA-LP protein, with the position of the corresponding exons opposite. Conserved regions are represented as well as the key positions. Phosphorylated serins are mentioned by an asterisk.

About 15% of BL tumors host a virus, which uses exclusively the W promoter, expressing an EBV atypical latency program [49], harboring EBNA1, EBNA3A, 3B, 3C, and a truncated form of EBNA-LP. In these cases, EBV genome lacks the EBNA2gene and the unique Y1Y2 exons of EBNA-LP. This was firstly described in P3HR1 and Daudi BL cell lines [57]. Subsequently, these cells were shown to be more resistant to apoptosis than cells infected by wild-type virus, what would be related to the truncated shape of EBNA-LP.

Given the difficulty of sequencing repetitive regions, only few authors have sequenced the IR1 region, including the EBNA-LP coding region. Previous studies identified two EBNA-LP distinct isoforms, type 1 and type 2 variants, based on the presence of G8/T12 or V8/A12 in exon W1 [58]. The Q54R substitution was also described in exon W2 from an African type 2 spontaneous lymphoblastoid cell line LCL [59]. Despite this, a high degree of conservation was reported for the Wp promoter and the W1-W2 intron, while the most diversity was observed for the BWRF1 ORF, which only shows 80% homology between various strains, and for Y exons [60]. The sequence variations in the Y exons, and especially the Y2 exon, made it possible to define four main subgroups, called A, B, C, and Z. The Akata strain belongs to subgroup A and B95-8 to subgroup B. Subgroup Z is found in type 2 EBVs, and the C subtype is characterized by V95E and V102I. Finally, it has been reported that tumor-derived strains are more prone to interstrain genetic exchange in IR1 [60].

4.4 LMP1

LMP1 is considered to be the main oncogenic protein in EBV. LMP1 is a multifunctional self-aggregating protein essential for the transformation of human B cells and rodent fibroblasts [61]. It is a 386 aa protein comprising a 24 aa cytosolic N-terminal (NT) segment, a 162 aa portion consisting of six transmembrane (TM) domains, and a 200 aa cytosolic C-terminal (CT) domain (Figure 5) [62]. The NT domain plays an important role in the orientation and anchoring of LMP1 to the membrane and its constitutive aggregation, thus contributing to the transforming function of LMP1 [63]. The TM region is involved in the localization of LMP1 at the level of lipid rafts in the membrane, thus inducing its clustering to activate signaling from the CT tail. It is remarkable that the F38LWY41 pattern in the first transmembrane fragment (TM1) and a second pattern consisting of aa W98 in TM3 are essential for the association of TM domains (1–2) with TM domains (3–6) as well as for the oligomerization and signaling of LMP1 [64]. The CT part is involved in the activation of LMP1-induced cell signaling pathways, including two important regions, CTAR1/TES1 and CTAR2/TES2 (Carboxyl-Terminal Activating Region/Transformation Effector Site) critical for EBV-mediated B-cell growth transformation [65]. Together, these regions mimic CD40, a member of the tumor necrosis factor (TNF) receptor family and key B-cell costimulatory receptor, thus enabling the recruitment of cell adapters associated with the TNF receptor family, TNF receptor-associated factors (TRAFs). The CTAR1 region includes the P204-X-Q206-X-T208 consensus pattern necessary for the attachment of TRAF adapters, specifically TRAF1, TRAF2, TRAF3, and TRAF5 [66]. Within the CTAR2 region, the Y384-Y385-D386 pattern is essential for binding the TNF receptor-associated death domain (TRADD) adapter. There is a third region, CTAR3 (aa 232–350), that is not essential for in vitro B cell immortalization and is less well known [67]. In this region located between CTAR1 and CTAR2 (aa 253–302), a variable number of repeat 11 aa elements (4 repeats for B95-8) exist.

Figure 5.

Schematic representation of basic structure of LMP1 protein with the different motifs and their position. TM1–6: transmembrane domains 1–6. The FWLY pattern in TM1 and W98 in TM3 are essential for the association of TM1–2 with TM3–6 and oligomerization signaling. CTAR1–3: carboxyl-terminal activating regions 1–3. PQQAT pattern is necessary for the attachment of TRAF adapters. YYD pattern is essential for binding the TNF receptor-associated death domain (TRADD) adapter.

LMP1 acts principally as a viral pseudoreceptor, which regulates host cell signal transduction by constitutive activation of cell pathways as mitogen-activated protein kinase (MAPK) pathways and principally the extracellular regulated kinases 1 and 2 (ERK1/2), c-Jun amino-terminal kinases 1–3 (JNK1–3), and p38 isoform pathways. LMP1 also induces the phosphatidylinositol 3-kinase (PI3K) pathway, which contributes to survival signals [68] and transcription of activator protein 1 (AP1) [69], PI3K, and AP1 pathways, therefore playing a major role in proliferation and cell cycle control. LMP1 is also responsible for the activation of JAK/STAT and interferon regulatory factor 7 (IRF7) pathways and for aberrant constitutive NF-kB activation. Indeed, the CTAR1 PXQXT pattern is able to engage TRAFs, leading finally to the activation of noncanonical NF-kB pathway that controls processing of the NF-kB2/p100 precursor [70]. The CTAR2 YYD pattern is in turn implicated in the activation of the canonical NF-kB pathway [71] after binding of tumor necrosis factor receptor superfamily member 1A (TNFRSF1A)-associated via TRADD and receptor-inter-acting protein 1 (RIP1). A wider region of LMP1 seems to be responsible for binding RIP1 (aa 351–386), compared to TRADD (aa 375–386) [72]. NF-kB is considered to be the principal factor by which LMP1 regulates gene expression and modifies cell behavior [73]. Activation of NF-kB is associated with upregulation of anti-apoptotic genes [32, 74] and downregulation of pro-apoptotic factors, as well as induction of tumorigenesis-associated B-cell activation markers [75, 76]. CTAR3, less well defined, seems to activate SUMOylation pathways and participate in the maintenance of EBV latency and control of cell migration, a hallmark of oncogenesis [77, 78].

Besides its ability to transform B cells, during the latency state, LMP1 seems also to be able to facilitate the release of virions from B cells during lytic replication [32].

Variations in the LMP1 sequence have been widely studied, particularly in the context of its impact on clinical occurrence or evolution. A 30 bp deletion (del30), resulting in a 10 aa loss in the C-terminal (aa 343–352), was first described in the Cao cell isolate from a Chinese NPC [79]. In addition, this isolate harbored numerous substitutions. A high prevalence of the same deletion, as reviewed by Chang et al. [8], was found in Asian NPC biopsy tissues [80, 81], in lymphomas and EBV-related gastric cancers from Eastern Asia [82] and in Asian nasal NK/T-cell lymphomas [83, 84]. Del30 was shown to be often associated with the G335D mutation in NPC, and such strains were reported to have a greater transforming activity in vitro than the reference LMP1 [85, 86]. If the 30 bp deletion is partly localized to CTAR2, it does not alter NF-kB activation [87] and finally does not modify signaling properties [88]. However, it is clear that strains bearing del30 are selected over the wt-LMP1 variants in NK/T-cell lymphomas [83] and NPC tumors [89]. Given that del30 strains have been currently detected in normal carriers [90] or in various EBV-associated diseases [91], and, because of a low prevalence of del30 strains in samples from Africa, North America, and Europe [8, 92], it is generally admitted that LMP1 del30 may represent a geographic polymorphism rather than a disease-associated polymorphism [93]. In a study, we carried out in France in patients with NK/T lymphoma, we found a del30 EBV in 4/4 biopsies studied and in 46.1% of total blood samples analyzed, while in a control population, the deletion was present in 4.8% of cases [94]. Other deletions were also described, such as the rare C terminal 69 bp deletion reported to weakly activate the AP1 transcription factor [95], or the 15 bp deletion (aa 275–279) frequently encountered in Western Europe [94].

Otherwise, numerous substitutions have been described in LMP1 (Table 3), particularly in the N-terminal extremity. Some authors have made attempts to classify viral strains by taking into account these substitutions with the aim of highlighting a viral implication in certain pathologies [99]. Thus, Mainou and Raab-Traub [88] classified EBV into seven variants, namely Alaskan, China 1, China 2, Med+, Med-, NC, and B95-8, all having the same in vitro transforming potential and signaling properties. Zuercher et al. [98] mentioned two polymorphisms, I124V/I152L and F144I/D150A/L151I, which seem to be markers of increased NF-kB activation in vitro. Lei et al. [96] distinguished four models according to the substitutions occurring in both the LMP1 gene and its promoter. The patients suffering from NPC that they studied all carried a strain belonging to pattern B, while the BLs were distributed among the four patterns. Many authors recognize two evolutionarily distinct clusters, Asian-derived EBV strains including GD2, HKNPC1, and Akata strains and non-Asian and African/American strains including AG876, B95-8, and Mutu strains, suggesting that the LMP1 gene could be used as a geographic marker [25, 97].

ProteinRole/localizationMain properties
EBNA1LatencyInitiation of viral episome replication before mitosis
Mitotic segregation of EBV episomes
Transcription of other latency genes (Cp and LMPp enhancer)
Degradation of promyelocytic leukemia protein (PML) bodies
Cellular transcription regulation
EBNA2LatencyViral and cellular transcription factor
Initiation and maintenance of B cell immortalization
Blocking of methylation sites for BZLF-1 binding
EBNA-LPLatencyCoactivator of the transcriptional activator EBNA2
LMP1LatencySimilarity to constitutively activated CD40
Constitutive activation of cell pathways
Maintenance of EBV latency and control of cell migration
BNRF1TegumentEstablishment of latency and cell immortalization
Increase in the number of cellular centrioles
BPLF1TegumentDownregulation of viral ribonucleotide reductase (RR)
Disruption of damaged DNA repair
Decreasing of innate immunity
BKRF3TegumentDNA replication and repair—viral DNA mutagenesis prevention

Table 2.

Main properties of proteins developed in this chapter.

Region concernedMutationConsequence of the mutationReferences
E2D[86, 96]
H3R/L[86, 94, 96]
NT domain (24AA)R7S[86]
Mutation rate: 0.33G8A[86]
R13P[86, 97]
R17L[86, 97]
L25I/M[13, 86, 94, 9697]
TM1 (20AA)L33I[86]
Mutation rate: 0.15V43I[86, 94, 96]
D46N[86, 94, 96, 97]
S57A[86, 94, 96]
TM2 (21AA)M61I[86, 97]
Mutation rate: 0.19163 V/L[86, 94, 96, 97]
A82G[86, 97]
C84G/V[86, 97]
TM3 (21AA)I85LHomo-oligomerization and/or interaction with other molecules in lipid rafts[86, 94, 96, 97]
Mutation rate: 0.24T91I[86]
F106V/Y[86, 96, 97]
F112YHomo-oligomerization and/or interaction with other molecules in lipid rafts[94]
TM4 (21AA)G115A[86]
Mutation rate: 0.43W116C[86]
I122L[86, 94, 97]
I124G/VI124V + I152L: increased NF-κB activation in vitro[94, 96, 98]
L126F[86, 94, 96, 97]
M129IM129I: increased LMPI half-life in epithelial cells[86, 94, 96, 97]
TM5 (22AA)Mutation rate: 0.18F144I/DFI44I/D + D150A/L + L151I: increased NF-κB activation in vitro[86, 97, 98]
D150AD150A/L + F144I/D + LI511: increased NF-κB activation in vitro[86, 97, 98]
L151IL151I + F144I/D + D150A/L: increased NF-κB activation in vitro[86, 94, 96, 97, 98]
II52LI152L + I124V: increased NF-κB activation in vitro[94, 96, 98]
TM6 (21AA)L178M[86, 97]
Mutation rate: 0.05Q189P[86, 97]
S192T[86, 97]
G212STG212S: Erk activation, thus c-Fos induction and binding to API site[86, 94, 96, 97]
SNQ pattern (212–214) + del30 in NK/T biopsies
CTAR1 (45AA)H213NSNQ pattern (212–214) + del30 in NK/T biopsies[86, 94, 96]
Mutation rate: 0.15E214QSNQ pattern (212–214) + del30 in NK/T biopsies[86, 94, 96]
S229T[94, 97]
del275–279[86, 94]
D298A[86, 97]
CTAR3 (56AA)S309NS309N + del30 + dell5 in NK/T biopsies[86, 94, 96, 97]
Mutation rate: 0.20G318K[97]
Q322E/N/K[86, 94, 96, 97]
Q334R[86, 94, 96, 97]
G335D/S[86, 94, 97]
del343–352[23, 86, 94, 97]
L338S/P[86, 94, 96, 97]
G344A/D[86, 97]
CTAR2 (35AA)H352R[94, 97]
Mutation rate: 0.23G353D[86]
S366T/Q/AS366T: Erk activation, thus c-Fos induction and binding to API site[86, 94, 96, 97]

Table 3.

LMP1 mutations described in the literature.

Finally, it should be noted that LMP1 carries a molecular signature of accelerated evolution rate probably due to positive selection as deduced from a significant proportion of nonsignificant variations [26].

So, regarding LMP1, which is the most oncogenic latency protein, two geographic clusters appear to exist corresponding to an Asian variant and a non-Asiatic variant. The described 30 bp deletion is mainly present on Asian strains, and it shows an obvious tropism for nasopharynx. Although many substitutions have been described, little work is done to analyze changes in LMP1 properties based on these substitutions. NPC could be associated with a particular strain, but this remains to be confirmed.


5. Variability of tegument proteins

After the latency proteins, the tegument proteins carry the most changes, and among them, the most mutated are BNRF1, BPLF1, and BKRF3, which will be detailed, as well as BBRF2. This latter protein appears to play an important role in viral infectivity [100], but its structure and function are poorly known today. For this reason, BBRF2 will not be developed here.

5.1 BNRF1

EBV major tegument protein BNRF1 contains 1318 aa, and its structure is shown schematically in Figure 6. BNRF1 is a member of a protein family with homology to the cellular purine biosynthesis enzyme FGARAT. BNRF1 is involved in the establishment of latency and cell immortalization by hijacking the antiviral DAXX (death domain-associated protein-6) histone chaperone [101]. BNRF1 seems to have lost conventional purine biosynthesis activity. It forms a stable quaternary complex with DAXX histone-binding domain (HBD), H3.3 and H4 [102], responsible for BNRF1 localization to PML nuclear bodies involved in antiviral intrinsic resistance and transcriptional repression of host cells. In the presence of BNFR1, DAXX can no longer collaborate with ATRX to assemble histone variant H3.3 into repressive chromatin at GC-rich repetitive DNA. Binding to DAXX, histone H3.3 and histone H4 occur, respectively, via the BNRF1 DAXX interaction domain (DID) (aa 360–600) and BNRF1 residues 40–52 and 99–102. Huang et al. [102] demonstrated that the quaternary complex formation is abrogated when dual mutations V546D/L548D and D568A/D569A occurred on BRNF1 DID and is partially diminished in vitro in case of dual mutations Y390A/K461A and V546S/L548S on BNRF1 DID. BNRF1 mutations at K461A, Y390A/K461A, V546S/L548S or Y390A, V546A/L548A, and D568A/569A moderately or severely reduced BNRF1 colocalization at PML nuclear bodies, respectively. A PurM-like domain (610–976) and a GATase domain (1037–1318) were defined. It has also recently been shown that BNRF1 can cause an abnormal increase in the number of cellular centrioles [103]. This phenomenon can lead to aneuploidy or structural chromosome abnormalities and, possibly, to carcinogenesis. The gene regions concerned have not been described.

Figure 6.

Schematic representation of basic structure of BNRF1 protein with the different motifs and their position. H3.3 and H4 regions, respectively, involved in binding to H3.3 and H4. DID: DAXX-interaction domain, domain implicated in binding to DAXX (death-domain associated protein-6) histone chaperone. PurM-like domain and GATase domain were noted, as well as the different mutations discussed.

BNRF1 is reported to be one of the most frequently mutated tegument proteins. It is interesting to note that a nonsense mutation was described in C666–1, an EBV-positive NPC cell line, with no major structural alterations in the BNRF1-deleted virus [92].

So, the mutations described for BNRF1 do not appear to correspond to a particular geographical distribution. On the other hand, some mutations seem to be able to modify DNA chromatinization, thus affecting the transcription, and therefore have important consequences on cell functioning.

5.2 BPLF1

BPLF1, the largest EBV protein (3149 aa), is a late lytic tegument protein. BPLF1 possesses a deubiquitinating (DUB) activity. BPLF1 is able to downregulate viral ribonucleotide reductase (RR) activity, by deubiquitination of the large subunit RR1 [104], and to specifically deubiquitinate proliferating cell nuclear antigen (PCNA), a DNA polymerase processivity factor, thus disrupting the repair of damaged DNA [105]. By triggering activation of repair pathways and co-opting DNA repair and replication factors, the virus could create genomic instability. The DUB activity is carried by the first 246 aa of the N-terminal region, and the C61 residue of the catalytic triad (Cys-His-Asp) is essential for activity [104]. BPLF1 relocalizes Pol 𝜼 to nuclear sites of viral DNA production, thereby bypassing DNA damage [106]. This mechanism contributes to efficient production of infectious virus.

BPLF1 is also able to deubiquinate cell factors, such as TRAF6, NEMO, and IkBα, leading to TLR signaling inhibition through both MyD88- and TRIF-dependent pathways, thus decreasing innate immune responses by reduced NF-kB activation and proinflammatory cytokine production [107]. It is noteworthy that the same catalytic active site also carries a deneddylating activity shown to target cullin ring ligases, potentially affecting viral replication and infectivity [108]. The role of BPLF1 to help drive human B-cell immortalization and lymphoma formation has also been discussed [109].

Sequencing of various viral strains has shown that BPLF1 is one of the proteins with the greatest number of changes [20, 24, 110]. Most of these mutations are not analyzed in detail, but Kwok et al. [21], working on the sequences of eight NPC biopsy specimens, reported two nonsynonymous mutations in the N-terminal region of the protein that exhibit deubiquitinating activity. The same finding was reported by Simbiri et al. [110], who also described 3 C-terminal mutations (L2935P, P2987L, and R3005Q). A single-nucleotide deletion coupled with a single-nucleotide insertion three nucleotides away was reported by Zeng et al. [13] in a NPC strain. As a result, two aa substitutions (GA/EG) were predicted to occur. Tu et al. [24] undertook phylogenetic analysis based on several reported EBV genome sequences and some major genes as BPLF1. They observed that EBV Asian subtypes clustered as a separate branch from the non-Asian ones.

So, as with other proteins, it seems that the Asian strains carry a protein different from the other strains. Substitutions occurring in the region carrying the deubiquitinase activity could have biological consequences.

5.3 BKRF3

BKRF3 is a small protein (255 aa), which belongs to the early lytic gene family, and encodes an uracil-DNA glycosylase (UDG), which removes inappropriate uracil residues from DNA. BKRF3 excises uracil bases incorporated in double-stranded DNA due to uracil misincorporation or more often cytosine deamination [111112]. BKRF3 participates in DNA replication and repair and prevents viral DNA mutagenesis. BKRF3 shares substantial similarity in overall structure with the one UDG family. Four of the five catalytic motifs are completely conserved (aa 90–94, 110–114, 146–149, 191–192), whereas the fifth domain (aa 213–229) carries a seven-residue insertion in the leucine loop [113]. In addition, the 29 N-terminal aa carry a nuclear localization signal (sequence KRKQ). Only changes in BKRF3 that do not severely affect viral replication can be retained, but it may be considered that these mutations cause a change in virus-cell interrelations.


6. Conclusion

The aim of this chapter was to take stock of the most frequently observed variations in the EBV genome and more particularly to see if some of these variations are considered to be involved in tumor pathology. The candidate viral genes concerned are numerous; those developed here are the most affected, and the mutations reported in the literature have been identified. Some mutations have been well studied, in particular as regards their impact on the structure or functionality of the protein or the cellular consequences of these modifications. However, most mutations have only been described. If a tumorigenic impact of viral mutations is not yet certain, many authors agree that geographic variants exist, and it seems clear that Asian strains have different characteristics from non-Asian strains. Further work is necessary to complete the mass of information and analysis, not at the level of one or several genes, but at the level of the entire genome.


  1. 1. Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from BURKITT’S lymphoma. Lancet. 1964;1:702-703. DOI: 10.1016/s0140-6736(64)91524-7
  2. 2. Zur Hausen H, Schulte-Holthausen H. Presence of EB virus nucleic acid homology in a “virus-free” line of Burkitt tumour cells. Nature. 1970;227:245-248. DOI: 10.1038/227245a0
  3. 3. Aozasa K, Takakuwa T, Hongyo T, Yang W-I. Nasal NK/T-cell lymphoma: Epidemiology and pathogenesis. International Journal of Hematology. 2008;87:110-117. DOI: 10.1007/s12185-008-0021-7
  4. 4. Weiss LM, Movahed LA, Warnke RA, Sklar J. Detection of Epstein-Barr viral genomes in reed-Sternberg cells of Hodgkin’s disease. The New England Journal of Medicine. 1989;320:502-506. DOI: 10.1056/NEJM198902233200806
  5. 5. Hamilton-Dutoit SJ, Pallesen G, Franzmann MB, Karkov J, Black F, Skinhøj P, et al. AIDS-related lymphoma. Histopathology, immunophenotype, and association with Epstein-Barr virus as demonstrated by in situ nucleic acid hybridization. The American Journal of Pathology. 1991;138:149-163
  6. 6. Klein G, Giovanella BC, Lindahl T, Fialkow PJ, Singh S, Stehlin JS. Direct evidence for the presence of Epstein-Barr virus DNA and nuclear antigen in malignant epithelial cells from patients with poorly differentiated carcinoma of the nasopharynx. Proceedings of the National Academy of Sciences of the United States of America. 1974;71:4737-4741. DOI: 10.1073/pnas.71.12.4737
  7. 7. Imai S, Koizumi S, Sugiura M, Tokunaga M, Uemura Y, Yamamoto N, et al. Gastric carcinoma: Monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein. Proceedings of the National Academy of Sciences of the United States of America. 1994;91:9131-9135. DOI: 10.1073/pnas.91.19.9131
  8. 8. Chang CM, Yu KJ, Mbulaiteye SM, Hildesheim A, Bhatia K. The extent of genetic diversity of Epstein-Barr virus and its geographic and disease patterns: A need for reappraisal. Virus Research. 2009;143:209-221. DOI: 10.1016/j.virusres.2009.07.005
  9. 9. Ziegler JL. Burkitt’s lymphoma. The New England Journal of Medicine. 1981;305:735-745. DOI: 10.1056/NEJM198109243051305
  10. 10. Kumar S, Mahanta J. Aetiology of nasopharyngeal carcinoma. A review. Indian Journal of Cancer. 1998;35:47-56
  11. 11. Baer R, Bankier AT, Biggin MD, Deininger PL, Farrell PJ, Gibson TJ, et al. DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature. 1984;310:207-211. DOI: 10.1038/310207a0
  12. 12. Dolan A, Addison C, Gatherer D, Davison AJ, McGeoch DJ. The genome of Epstein-Barr virus type 2 strain AG876. Virology. 2006;350:164-170. DOI: 10.1016/j.virol.2006.01.015
  13. 13. Zeng M-S, Li D-J, Liu Q-L, Song L-B, Li M-Z, Zhang R-H, et al. Genomic sequence analysis of Epstein-Barr virus strain GD1 from a nasopharyngeal carcinoma patient. Journal of Virology. 2005;79:15323-15330. DOI: 10.1128/JVI.79.24.15323-15330.2005
  14. 14. Bhatia K, Raj A, Guitierrez MI, Judde JG, Spangler G, Venkatesh H, et al. Variation in the sequence of Epstein Barr virus nuclear antigen 1 in normal peripheral blood lymphocytes and in Burkitt’s lymphomas. Oncogene. 1996;13:177-181
  15. 15. Walling DM, Shebib N, Weaver SC, Nichols CM, Flaitz CM, Webster-Cyriaque J. The molecular epidemiology and evolution of Epstein-Barr virus: Sequence variation and genetic recombination in the latent membrane protein-1 gene. The Journal of Infectious Diseases. 1999;179:763-774. DOI: 10.1086/314672
  16. 16. Adldinger HK, Delius H, Freese UK, Clarke J, Bornkamm GW. A putative transforming gene of Jijoye virus differs from that of Epstein-Barr virus prototypes. Virology. 1985;141:221-234. DOI: 10.1016/0042-6822(85)90253-3
  17. 17. Sample J, Young L, Martin B, Chatman T, Kieff E, Rickinson A, et al. Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes. Journal of Virology. 1990;64:4084-4092
  18. 18. Tzellos S, Farrell PJ. Epstein-Barr virus sequence variation-biology and disease. Pathogens. 2012;1:156-174. DOI: 10.3390/pathogens1020156
  19. 19. Liu P, Fang X, Feng Z, Guo Y-M, Peng R-J, Liu T, et al. Direct sequencing and characterization of a clinical isolate of Epstein-Barr virus from nasopharyngeal carcinoma tissue by using next-generation sequencing technology. Journal of Virology. 2011;85:11291-11299. DOI: 10.1128/JVI.00823-11
  20. 20. Kwok H, Tong AHY, Lin CH, Lok S, Farrell PJ, Kwong DLW, et al. Genomic sequencing and comparative analysis of Epstein-Barr virus genome isolated from primary nasopharyngeal carcinoma biopsy. PLoS One. 2012;7:e36939. DOI: 10.1371/journal.pone.0036939
  21. 21. Kwok H, Wu CW, Palser AL, Kellam P, Sham PC, Kwong DLW, et al. Genomic diversity of Epstein-Barr virus genomes isolated from primary nasopharyngeal carcinoma biopsy samples. Journal of Virology. 2014;88:10662-10672. DOI: 10.1128/JVI.01665-14
  22. 22. Palser AL, Grayson NE, White RE, Corton C, Correia S, Ba Abdullah MM, et al. Genome diversity of Epstein-Barr virus from multiple tumor types and normal infection. Journal of Virology. 2015;89:5222-5237. DOI: 10.1128/JVI.03614-14
  23. 23. Wang S, Xiong H, Yan S, Wu N, Lu Z. Identification and characterization of Epstein-Barr virus genomes in lung carcinoma biopsy samples by next-generation sequencing technology. Scientific Reports. 2016;6:26156. DOI: 10.1038/srep26156
  24. 24. Tu C, Zeng Z, Qi P, Li X, Guo C, Xiong F, et al. Identification of genomic alterations in nasopharyngeal carcinoma and nasopharyngeal carcinoma-derived Epstein-Barr virus by whole-genome sequencing. Carcinogenesis. 2018;39:1517-1528. DOI: 10.1093/carcin/bgy108
  25. 25. Liu Y, Yang W, Pan Y, Ji J, Lu Z, Ke Y. Genome-wide analysis of Epstein-Barr virus (EBV) isolated from EBV-associated gastric carcinoma (EBVaGC). Oncotarget. 2016;7:4903-4914. DOI: 10.18632/oncotarget.6751
  26. 26. Santpere G, Darre F, Blanco S, Alcami A, Villoslada P, Mar Albà M, et al. Genome-wide analysis of wild-type Epstein-Barr virus genomes derived from healthy individuals of the 1,000 genomes project. Genome Biology and Evolution. 2014;6:846-860. DOI: 10.1093/gbe/evu054
  27. 27. Peng R-J, Han B-W, Cai Q-Q , Zuo X-Y, Xia T, Chen J-R, et al. Genomic and transcriptomic landscapes of Epstein-Barr virus in extranodal natural killer T-cell lymphoma. Leukemia. 2019;33:1451-1462. DOI: 10.1038/s41375-018-0324-5
  28. 28. Yang Z. PAML 4: Phylogenetic analysis by maximum likelihood. Molecular Biology and Evolution. 2007;24:1586-1591. DOI: 10.1093/molbev/msm088
  29. 29. Frappier L. The Epstein-Barr virus EBNA1 protein. Scientifica (Cairo). 2012;2012:438204. DOI: 10.6064/2012/438204
  30. 30. Wilson JB, Manet E, Gruffat H, Busson P, Blondel M, Fahraeus R. EBNA1: Oncogenic activity, immune evasion and biochemical functions provide targets for novel therapeutic strategies against Epstein-Barr virus-associated cancers. Cancers (Basel). 2018;10(4):109. 130 pages. DOI: 10.3390/cancers10040109
  31. 31. Young LS, Murray PG. Epstein-Barr virus and oncogenesis: From latent genes to tumours. Oncogene. 2003;22:5108-5121. DOI: 10.1038/sj.onc.1206556
  32. 32. Li C-W, Jheng B-R, Chen B-S. Investigating genetic-and-epigenetic networks, and the cellular mechanisms occurring in Epstein-Barr virus-infected human B lymphocytes via big data mining and genome-wide two-sided NGS data identification. PLoS One. 2018;13:e0202537. DOI: 10.1371/journal.pone.0202537
  33. 33. Deakyne JS, Malecka KA, Messick TE, Lieberman PM. Structural and functional basis for an EBNA1 hexameric ring in Epstein-Barr virus episome maintenance. Journal of Virology. 2017;91(19):17 pages. DOI: 10.1128/JVI.01046-17
  34. 34. Habeshaw G, Yao QY, Bell AI, Morton D, Rickinson AB. Epstein-Barr virus nuclear antigen 1 sequences in endemic and sporadic Burkitt’s lymphoma reflect virus strains prevalent in different geographic areas. Journal of Virology. 1999;73:965-975
  35. 35. Gutiérrez MI, Raj A, Spangler G, Sharma A, Hussain A, Judde JG, et al. Sequence variations in EBNA-1 may dictate restriction of tissue distribution of Epstein-Barr virus in normal and tumour cells. The Journal of General Virology. 1997;78(Pt 7):1663-1670. DOI: 10.1099/0022-1317-78-7-1663
  36. 36. Wang W-Y, Chien Y-C, Jan J-S, Chueh C-M, Lin J-C. Consistent sequence variation of Epstein-Barr virus nuclear antigen 1 in primary tumor and peripheral blood cells of patients with nasopharyngeal carcinoma. Clinical Cancer Research. 2002;8:2586-2590
  37. 37. Zhang X-S, Wang H-H, Hu L-F, Li A, Zhang R-H, Mai H-Q , et al. V-val subtype of Epstein-Barr virus nuclear antigen 1 preferentially exists in biopsies of nasopharyngeal carcinoma. Cancer Letters. 2004;211:11-18. DOI: 10.1016/j.canlet.2004.01.035
  38. 38. Sandvej K, Zhou XG, Hamilton-Dutoit S. EBNA-1 sequence variation in Danish and Chinese EBV-associated tumours: Evidence for geographical polymorphism but not for tumour-specific subtype restriction. The Journal of Pathology. 2000;191:127-131. DOI: 10.1002/(SICI)1096-9896(200006)191:2<127::AID-PATH614>3.0.CO;2-E
  39. 39. Borozan I, Zapatka M, Frappier L, Ferretti V. Analysis of Epstein-Barr virus genomes and expression profiles in gastric adenocarcinoma. Journal of Virology. 2018;92(2):17 pages. DOI: 10.1128/JVI.01239-17
  40. 40. Dheekollu J, Malecka K, Wiedmer A, Delecluse H-J, Chiang AKS, Altieri DC, et al. Carcinoma-risk variant of EBNA1 deregulates Epstein-Barr virus episomal latency. Oncotarget. 2017;8:7248-7264. DOI: 10.18632/oncotarget.14540
  41. 41. Wang X, Wang Y, Wu G, Chao Y, Sun Z, Luo B. Sequence analysis of Epstein-Barr virus EBNA-2 gene coding amino acid 148-487 in nasopharyngeal and gastric carcinomas. Virology Journal. 2012;9:49. DOI: 10.1186/1743-422X-9-49
  42. 42. Friberg A, Thumann S, Hennig J, Zou P, Nössner E, Ling PD, et al. The EBNA-2 N-terminal transactivation domain folds into a dimeric structure required for target gene activation. PLoS Pathogens. 2015;11:e1004910. DOI: 10.1371/journal.ppat.1004910
  43. 43. Tsui S, Schubach WH. Epstein-Barr virus nuclear protein 2A forms oligomers in vitro and in vivo through a region required for B-cell transformation. Journal of Virology. 1994;68:4287-4294
  44. 44. Rickinson AB, Young LS, Rowe M. Influence of the Epstein-Barr virus nuclear antigen EBNA 2 on the growth phenotype of virus-transformed B cells. Journal of Virology. 1987;61:1310-1317
  45. 45. Tzellos S, Correia PB, Karstegl CE, Cancian L, Cano-Flanagan J, McClellan MJ, et al. A single amino acid in EBNA-2 determines superior B lymphoblastoid cell line growth maintenance by Epstein-Barr virus type 1 EBNA-2. Journal of Virology. 2014;88:8743-8753. DOI: 10.1128/JVI.01000-14
  46. 46. Lu F, Chen H-S, Kossenkov AV, DeWispeleare K, Won K-J, Lieberman PM. EBNA2 drives formation of new chromosome binding sites and target genes for B-cell master regulatory transcription factors RBP-jκ and EBF1. PLoS Pathogens. 2016;12:e1005339. DOI: 10.1371/journal.ppat.1005339
  47. 47. Mühe J, Wang F. Species-specific functions of Epstein-Barr virus nuclear antigen 2 (EBNA2) reveal dual roles for initiation and maintenance of B cell immortalization. PLoS Pathogens. 2017;13:e1006772. DOI: 10.1371/journal.ppat.1006772
  48. 48. Peng C-W, Zhao B, Kieff E. Four EBNA2 domains are important for EBNALP coactivation. Journal of Virology. 2004;78:11439-11442. DOI: 10.1128/JVI.78.20.11439-11442.2004
  49. 49. Kelly G, Bell A, Rickinson A. Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2. Nature Medicine. 2002;8:1098-1104. DOI: 10.1038/nm758
  50. 50. Sinclair AJ, Palmero I, Peters G, Farrell PJ. EBNA-2 and EBNA-LP cooperate to cause G0 to G1 transition during immortalization of resting human B lymphocytes by Epstein-Barr virus. The EMBO Journal. 1994;13:3321-3328
  51. 51. Nitsche F, Bell A, Rickinson A. Epstein-Barr virus leader protein enhances EBNA-2-mediated transactivation of latent membrane protein 1 expression: A role for the W1W2 repeat domain. Journal of Virology. 1997;71:6619-6628
  52. 52. Kempkes B et al. EBNA2 and its coactivator EBNA-LP. In: Münz C, editor. Epstein Barr Virus. Vol. 2. One Herpes Virus: Many Diseases. Heidelberg, Berlin: Springer; 2015. pp. 35-59
  53. 53. Tierney RJ, Kao K-Y, Nagra JK, Rickinson AB. Epstein-Barr virus BamHI W repeat number limits EBNA2/EBNA-LP coexpression in newly infected B cells and the efficiency of B-cell transformation: A rationale for the multiple W repeats in wild-type virus strains. Journal of Virology. 2011;85:12362-12375. DOI: 10.1128/JVI.06059-11
  54. 54. Han I, Harada S, Weaver D, Xue Y, Lane W, Orstavik S, et al. EBNA-LP associates with cellular proteins including DNA-PK and HA95. Journal of Virology. 2001;75:2475-2481. DOI: 10.1128/JVI.75.5.2475-2481.2001
  55. 55. Woisetschlaeger M, Yandava CN, Furmanski LA, Strominger JL, Speck SH. Promoter switching in Epstein-Barr virus during the initial stages of infection of B lymphocytes. Proceedings of the National Academy of Sciences of the United States of America. 1990;87:1725-1729. DOI: 10.1073/pnas.87.5.1725
  56. 56. Chelouah S, Cochet E, Couvé S, Balkaran S, Robert A, May E, et al. New interactors of the truncated EBNA-LP protein identified by mass spectrometry in P3HR1 Burkitt’s lymphoma cells. Cancers (Basel). 2018;10(12):14 pages. DOI: 10.3390/cancers10010012
  57. 57. Jones MD, Foster L, Sheedy T, Griffin BE. The EB virus genome in Daudi Burkitt’s lymphoma cells has a deletion similar to that observed in a non-transforming strain (P3HR-1) of the virus. The EMBO Journal. 1984;3:813-821
  58. 58. Finke J, Rowe M, Kallin B, Ernberg I, Rosén A, Dillner J, et al. Monoclonal and polyclonal antibodies against Epstein-Barr virus nuclear antigen 5 (EBNA-5) detect multiple protein species in Burkitt’s lymphoma and lymphoblastoid cell lines. Journal of Virology. 1987;61:3870-3878
  59. 59. McCann EM, Kelly GL, Rickinson AB, Bell AI. Genetic analysis of the Epstein-Barr virus-coded leader protein EBNA-LP as a co-activator of EBNA2 function. The Journal of General Virology. 2001;82:3067-3079. DOI: 10.1099/0022-1317-82-12-3067
  60. 60. Ba Abdullah MM, Palermo RD, Palser AL, Grayson NE, Kellam P, Correia S, et al. Heterogeneity of the Epstein-Barr virus (EBV) major internal repeat reveals evolutionary mechanisms of EBV and a functional defect in the prototype EBV strain B95-8. Journal of Virology. 2017;91(23):25 pages. DOI: 10.1128/JVI.00920-17
  61. 61. Dirmeier U, Neuhierl B, Kilger E, Reisbach G, Sandberg ML, Hammerschmidt W. Latent membrane protein 1 is critical for efficient growth transformation of human B cells by Epstein-Barr virus. Cancer Research. 2003;63:2982-2989
  62. 62. Li H-P, Chang Y-S. Epstein-Barr virus latent membrane protein 1: Structure and functions. Journal of Biomedical Science. 2003;10:490-504. DOI: 10.1007/bf02256110
  63. 63. Coffin WF, Erickson KD, Hoedt-Miller M, Martin JM. The cytoplasmic amino-terminus of the latent membrane protein-1 of Epstein-Barr virus: Relationship between transmembrane orientation and effector functions of the carboxy-terminus and transmembrane domain. Oncogene. 2001;20:5313-5330. DOI: 10.1038/sj.onc.1204689
  64. 64. Yasui T, Luftig M, Soni V, Kieff E. Latent infection membrane protein transmembrane FWLY is critical for intermolecular interaction, raft localization, and signaling. Proceedings of the National Academy of Sciences of the United States of America. 2004;101:278-283. DOI: 10.1073/pnas.2237224100
  65. 65. Izumi KM, Kaye KM, Kieff ED. The Epstein-Barr virus LMP1 amino acid sequence that engages tumor necrosis factor receptor associated factors is critical for primary B lymphocyte growth transformation. Proceedings of the National Academy of Sciences of the United States of America. 1997;94:1447-1452. DOI: 10.1073/pnas.94.4.1447
  66. 66. Mosialos G, Birkenbach M, Yalamanchili R, VanArsdale T, Ware C, Kieff E. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell. 1995;80:389-399. DOI: 10.1016/0092-8674(95)90489-1
  67. 67. Izumi KM, Cahir McFarland ED, Riley EA, Rizzo D, Chen Y, Kieff E. The residues between the two transformation effector sites of Epstein-Barr virus latent membrane protein 1 are not critical for B-lymphocyte growth transformation. Journal of Virology. 1999;73:9908-9916
  68. 68. Dawson CW, Tramountanis G, Eliopoulos AG, Young LS. Epstein-Barr virus latent membrane protein 1 (LMP1) activates the phosphatidylinositol 3-kinase/Akt pathway to promote cell survival and induce actin filament remodeling. The Journal of Biological Chemistry. 2003;278:3694-3704. DOI: 10.1074/jbc.M209840200
  69. 69. Kieser A, Kilger E, Gires O, Ueffing M, Kolch W, Hammerschmidt W. Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade. The EMBO Journal. 1997;16:6478-6485. DOI: 10.1093/emboj/16.21.6478
  70. 70. Lavorgna A, Harhaj EW. EBV LMP1: New and shared pathways to NF-κB activation. Proceedings of the National Academy of Sciences of the United States of America. 2012;109:2188-2189. DOI: 10.1073/pnas.1121357109
  71. 71. Gewurz BE, Mar JC, Padi M, Zhao B, Shinners NP, Takasaki K, et al. Canonical NF-kappaB activation is essential for Epstein-Barr virus latent membrane protein 1 TES2/CTAR2 gene regulation. Journal of Virology. 2011;85:6764-6773. DOI: 10.1128/JVI.00422-11
  72. 72. Eliopoulos AG, Young LS. LMP1 structure and signal transduction. Seminars in Cancer Biology. 2001;11:435-444. DOI: 10.1006/scbi.2001.0410
  73. 73. Cahir-McFarland ED, Carter K, Rosenwald A, Giltnane JM, Henrickson SE, Staudt LM, et al. Role of NF-kappa B in cell survival and transcription of latent membrane protein 1-expressing or Epstein-Barr virus latency III-infected cells. Journal of Virology. 2004;78:4108-4119. DOI: 10.1128/jvi.78.8.4108-4119.2004
  74. 74. Calderwood MA, Venkatesan K, Xing L, Chase MR, Vazquez A, Holthaus AM, et al. Epstein-Barr virus and virus human protein interaction maps. Proceedings of the National Academy of Sciences of the United States of America. 2007;104:7606-7611. DOI: 10.1073/pnas.0702332104
  75. 75. Liu M-T, Chang Y-T, Chen S-C, Chuang Y-C, Chen Y-R, Lin C-S, et al. Epstein-Barr virus latent membrane protein 1 represses p53-mediated DNA repair and transcriptional activity. Oncogene. 2005;24:2635-2646. DOI: 10.1038/sj.onc.1208319
  76. 76. Wang LW, Jiang S, Gewurz BE. Epstein-Barr virus LMP1-mediated oncogenicity. Journal of Virology. 2017;91(21):11 pages. DOI: 10.1128/JVI.01718-16
  77. 77. Bentz GL, Whitehurst CB, Pagano JS. Epstein-Barr virus latent membrane protein 1 (LMP1) C-terminal-activating region 3 contributes to LMP1-mediated cellular migration via its interaction with Ubc9. Journal of Virology. 2011;85:10144-10153. DOI: 10.1128/JVI.05035-11
  78. 78. Bentz GL, Moss CR, Whitehurst CB, Moody CA, Pagano JS. LMP1-induced sumoylation influences the maintenance of Epstein-Barr virus latency through KAP1. Journal of Virology. 2015;89:7465-7477. DOI: 10.1128/JVI.00711-15
  79. 79. Hu LF, Zabarovsky ER, Chen F, Cao SL, Ernberg I, Klein G, et al. Isolation and sequencing of the Epstein-Barr virus BNLF-1 gene (LMP1) from a Chinese nasopharyngeal carcinoma. The Journal of General Virology. 1991;72(Pt 10):2399-2409. DOI: 10.1099/0022-1317-72-10-2399
  80. 80. Miller WE, Edwards RH, Walling DM, Raab-Traub N. Sequence variation in the Epstein-Barr virus latent membrane protein 1. The Journal of General Virology. 1994;75(Pt 10):2729-2740. DOI: 10.1099/0022-1317-75-10-2729
  81. 81. Tan E-L, Peh S-C, Sam C-K. Analyses of Epstein-Barr virus latent membrane protein-1 in Malaysian nasopharyngeal carcinoma: High prevalence of 30-bp deletion, Xho1 polymorphism and evidence of dual infections. Journal of Medical Virology. 2003;69:251-257. DOI: 10.1002/jmv.10282
  82. 82. Mori S, Itoh T, Tokunaga M, Eizuru Y. Deletions and single-base mutations within the carboxy-terminal region of the latent membrane protein 1 oncogene in Epstein-Barr virus-related gastric cancers of southern Japan. Journal of Medical Virology. 1999;57:152-158. DOI: 10.1002/(sici)1096-9071(199902)57:2<152::aid-jmv11>;2-k
  83. 83. Chiang AK, Wong KY, Liang AC, Srivastava G. Comparative analysis of Epstein-Barr virus gene polymorphisms in nasal T/NK-cell lymphomas and normal nasal tissues: Implications on virus strain selection in malignancy. International Journal of Cancer. 1999;80:356-364. DOI: 10.1002/(sici)1097-0215(19990129)80:3<356::aid-ijc4>;2-d
  84. 84. Nagamine M, Takahara M, Kishibe K, Nagato T, Ishii H, Bandoh N, et al. Sequence variations of Epstein-Barr virus LMP1 gene in nasal NK/T-cell lymphoma. Virus Genes. 2007;34:47-54. DOI: 10.1007/s11262-006-0008-5
  85. 85. Li SN, Chang YS, Liu ST. Effect of a 10-amino acid deletion on the oncogenic activity of latent membrane protein 1 of Epstein-Barr virus. Oncogene. 1996;12:2129-2135
  86. 86. Cheung ST, Leung SF, Lo KW, Chiu KW, Tam JS, Fok TF, et al. Specific latent membrane protein 1 gene sequences in type 1 and type 2 Epstein-Barr virus from nasopharyngeal carcinoma in Hong Kong. International Journal of Cancer. 1998;76:399-406. DOI: 10.1002/(sici)1097-0215(19980504)76:3<399::aid-ijc18>;2-6
  87. 87. Farrell PJ. Signal transduction from the Epstein-Barr virus LMP-1 transforming protein. Trends in Microbiology. 1998;6:175-177; discussion 177-178. DOI: 10.1016/s0966-842x(98)01262-1
  88. 88. Mainou BA, Raab-Traub N. LMP1 strain variants: Biological and molecular properties. Journal of Virology. 2006;80:6458-6468. DOI: 10.1128/JVI.00135-06
  89. 89. Edwards RH, Sitki-Green D, Moore DT, Raab-Traub N. Potential selection of LMP1 variants in nasopharyngeal carcinoma. Journal of Virology. 2004;78:868-881. DOI: 10.1128/jvi.78.2.868-881.2004
  90. 90. Correa RM, Fellner MD, Alonio LV, Durand K, Teyssié AR, Picconi MA. Epstein-Barr virus (EBV) in healthy carriers: Distribution of genotypes and 30 bp deletion in latent membrane protein-1 (LMP-1) oncogene. Journal of Medical Virology. 2004;73:583-588. DOI: 10.1002/jmv.20129
  91. 91. Lorenzetti MA, Gantuz M, Altcheh J, De Matteo E, Chabay PA, Preciado MV. Distinctive Epstein-Barr virus variants associated with benign and malignant pediatric pathologies: LMP1 sequence characterization and linkage with other viral gene polymorphisms. Journal of Clinical Microbiology. 2012;50:609-618. DOI: 10.1128/JCM.05778-11
  92. 92. Tso KK-Y, Yip KY-L, Mak CK-Y, Chung GT-Y, Lee S-D, Cheung S-T, et al. Complete genomic sequence of Epstein-Barr virus in nasopharyngeal carcinoma cell line C666-1. Infectious Agents and Cancer. 2013;8:29. DOI: 10.1186/1750-9378-8-29
  93. 93. Zhang X-S, Song K-H, Mai H-Q , Jia W-H, Feng B-J, Xia J-C, et al. The 30-bp deletion variant: A polymorphism of latent membrane protein 1 prevalent in endemic and non-endemic areas of nasopharyngeal carcinomas in China. Cancer Letters. 2002;176:65-73. DOI: 10.1016/s0304-3835(01)00733-9
  94. 94. Halabi MA, Jaccard A, Moulinas R, Bahri R, Al Mouhammad H, Mammari N, et al. Clonal deleted latent membrane protein 1 variants of Epstein-Barr virus are predominant in European extranodal NK/T lymphomas and disappear during successful treatment. International Journal of Cancer. 2016;139:793-802. DOI: 10.1002/ijc.30128
  95. 95. Larcher C, Bernhard D, Schaadt E, Adler B, Ausserlechner MJ, Mitterer M, et al. Functional analysis of the mutated Epstein-Barr virus oncoprotein LMP1(69del): Implications for a new role of naturally occurring LMP1 variants. Haematologica. 2003;88:1324-1335
  96. 96. Lei H, Li T, Li B, Tsai S, Biggar RJ, Nkrumah F, et al. Epstein-Barr virus from Burkitt lymphoma biopsies from Africa and South America share novel LMP-1 promoter and gene variations. Scientific Reports. 2015;5:16706. DOI: 10.1038/srep16706
  97. 97. Lin Z, Wang X, Strong MJ, Concha M, Baddoo M, Xu G, et al. Whole-genome sequencing of the Akata and Mutu Epstein-Barr virus strains. Journal of Virology. 2013;87:1172-1182. DOI: 10.1128/JVI.02517-12
  98. 98. Zuercher E, Butticaz C, Wyniger J, Martinez R, Battegay M, Boffi El Amari E, et al. Genetic diversity of EBV-encoded LMP1 in the Swiss HIV Cohort Study and implication for NF-κb activation. PLoS One. 2012;7:e32168. DOI: 10.1371/journal.pone.0032168
  99. 99. Edwards RH, Seillier-Moiseiwitsch F, Raab-Traub N. Signature amino acid changes in latent membrane protein 1 distinguish Epstein-Barr virus strains. Virology. 1999;261:79-95. DOI: 10.1006/viro.1999.9855
  100. 100. Masud HMAA, Yanagi Y, Watanabe T, Sato Y, Kimura H, Murata T. Epstein-Barr virus BBRF2 is required for maximum infectivity. Microorganisms. 2019;7(705):14 pages. DOI: 10.3390/microorganisms7120705
  101. 101. Tsai K, Thikmyanova N, Wojcechowskyj JA, Delecluse H-J, Lieberman PM. EBV tegument protein BNRF1 disrupts DAXX-ATRX to activate viral early gene transcription. PLoS Pathogens. 2011;7:e1002376. DOI: 10.1371/journal.ppat.1002376
  102. 102. Huang H, Deng Z, Vladimirova O, Wiedmer A, Lu F, Lieberman PM, et al. Structural basis underlying viral hijacking of a histone chaperone complex. Nature Communications. 2016;7:12707. DOI: 10.1038/ncomms12707
  103. 103. Shumilov A, Tsai M-H, Schlosser YT, Kratz A-S, Bernhardt K, Fink S, et al. Epstein-Barr virus particles induce centrosome amplification and chromosomal instability. Nature Communications. 2017;8:14257. DOI: 10.1038/ncomms14257
  104. 104. Whitehurst CB, Ning S, Bentz GL, Dufour F, Gershburg E, Shackelford J, et al. The Epstein-Barr virus (EBV) deubiquitinating enzyme BPLF1 reduces EBV ribonucleotide reductase activity. Journal of Virology. 2009;83:4345-4353. DOI: 10.1128/JVI.02195-08
  105. 105. Whitehurst CB, Vaziri C, Shackelford J, Pagano JS. Epstein-Barr virus BPLF1 deubiquitinates PCNA and attenuates polymerase η recruitment to DNA damage sites. Journal of Virology. 2012;86:8097-8106. DOI: 10.1128/JVI.00588-12
  106. 106. Dyson OF, Pagano JS, Whitehurst CB. The translesion polymerase pol η is required for efficient Epstein-Barr virus infectivity and is regulated by the viral deubiquitinating enzyme BPLF1. Journal of Virology. 2017;91(19):14 pages. DOI: 10.1128/JVI.00600-17
  107. 107. van Gent M, Braem SGE, de Jong A, Delagic N, Peeters JGC, Boer IGJ, et al. Epstein-Barr virus large tegument protein BPLF1 contributes to innate immune evasion through interference with toll-like receptor signaling. PLoS Pathogens. 2014;10:e1003960. DOI: 10.1371/journal.ppat.1003960
  108. 108. Gastaldello S, Hildebrand S, Faridani O, Callegari S, Palmkvist M, Guglielmo CD, et al. A deneddylase encoded by Epstein–Barr virus promotes viral DNA replication by regulating the activity of cullin-RING ligases. Nature Cell Biology. 2010;12:351-361. DOI: 10.1038/ncb2035
  109. 109. Whitehurst CB, Li G, Montgomery SA, Montgomery ND, Su L, Pagano JS. Knockout of Epstein-Barr virus BPLF1 retards B-cell transformation and lymphoma formation in humanized mice. MBio. 2015;6(5):11 pages. DOI: 10.1128/mBio.01574-15
  110. 110. Simbiri KO, Smith NA, Otieno R, Wohlford EEM, Daud II, Odada SP, et al. Epstein-Barr virus genetic variation in lymphoblastoid cell lines derived from Kenyan pediatric population. PLoS One. 2015;10:e0125420. DOI: 10.1371/journal.pone.0125420
  111. 111. Lu C-C, Huang H-T, Wang J-T, Slupphaug G, Li T-K, Wu M-C, et al. Characterization of the uracil-DNA glycosylase activity of Epstein-Barr virus BKRF3 and its role in lytic viral DNA replication. Journal of Virology. 2007;81:1195-1208. DOI: 10.1128/JVI.01518-06
  112. 112. Su M-T, Liu I-H, Wu C-W, Chang S-M, Tsai C-H, Yang P-W, et al. Uracil DNA glycosylase BKRF3 contributes to Epstein-Barr virus DNA replication through physical interactions with proteins in viral DNA replication complex. Journal of Virology. 2014;88:8883-8899. DOI: 10.1128/JVI.00950-14
  113. 113. Géoui T, Buisson M, Tarbouriech N, Burmeister WP. New insights on the role of the gamma-herpesvirus uracil-DNA glycosylase leucine loop revealed by the structure of the Epstein-Barr virus enzyme in complex with an inhibitor protein. Journal of Molecular Biology. 2007;366:117-131. DOI: 10.1016/j.jmb.2006.11.007

Written By

Sylvie Ranger-Rogez

Submitted: 01 May 2020 Reviewed: 16 June 2020 Published: 19 August 2020